Boston University Alzheimer's Disease Research Center

波士顿大学阿尔茨海默病研究中心

基本信息

批准号：
10468304
负责人：
Ann C. McKee
金额：
$ 322.91万
依托单位：
BOSTON UNIVERSITY MEDICAL CAMPUS
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-15 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10468304
关键词：
Address Advocacy Affect Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer&apos s disease risk Amyloid Amyloid beta-Protein Amyloid deposition Biological Biological Markers Biometry Blood Blood Vessels Books Boston Brain Concussion Cerebral Amyloid Angiopathy Clinic Clinical Clinical Data Cognitive Collaborations Communities Consultations Data Data Analyses Data Collection Data Set Deposition Development Electroencephalography Ensure Environmental Risk Factor Exposure to Foundations Framingham Heart Study Funding Future General Population Genetic Goals Grant Growth Heart Heterogeneity Impaired cognition Individual Infrastructure Late Effects Lewy Body Disease Liquid substance Longevity Magnetic Resonance Imaging Mission Modeling Molecular Profiling Nature Nuclear Pore Complex Participant Pathologic Pathology Phenotype Positioning Attribute Positron-Emission Tomography Prevention Privatization Recommendation Research Research Personnel Research Support Research Training Resources Risk Risk Factors Sampling Scientist Secure Source Specimen Spinal Puncture Strategic vision Tauopathies Training United States National Institutes of Health Universities Women&apos s Health age related analytical tool biomarker discovery black women career development catalyst chronic traumatic encephalopathy cohort community engagement contact sports data management digital digital health education research experience follow-up genetic profiling head impact health assessment high risk human subject innovation interest military service molecular phenotype motor neuron degeneration neuroimaging neuroinflammation neuropathology next generation outreach outreach program prevent programs protein TDP-43 public-private partnership recruit research clinical testing research study statistics symposium tau Proteins white matter

项目摘要

The Boston University Alzheimer's Disease Research Center (BU ADRC) is committed to the goals and strategies of NAPA including: to prevent and effectively treat AD and AD related dementias (ADRD) by 2025 by expanding AD/ADRD research; to accelerate efforts to identify early and pre-symptomatic stages of AD/ADRD; and to educate the public about AD/ADRD. BU ADRC research themes are congruent with NIH AD/ADRD Research Summit recommendations including: 1) research on heterogeneity and the multifactorial nature of AD/ADRD; 2) molecular profiling of existing and new cohorts; and 3) developing new public-private partnerships. We operationalize our mission through 7 tightly integrated cores: Administrative, Clinical (CC), Data Management and Statistics (DMS), Biomarker, Neuropathology (NPC), Outreach/Recruitment, Engagement (ORE), Genetics and Molecular Profiling (GMP) and a research education component (REC). The Cores are focused on cutting edge research, proactive community engagement, training the next generation of AD/ADRD clinicians and researchers, and sharing key material, data, and expertise both among key partners and with the community at large. The BU ADRC has made significant contributions to the remarkable growth of AD/ADRD research nationally and has actively contributed participants, biological samples, clinical data, and scientific expertise to all major national AD/ADRD research initiatives. The BU ADRC has been the catalyst for exciting new research on genetic and lifespan environmental risk factors and AD/ADRD, particularly vascular risk and exposure to repetitive head impacts (RHI) from contact sports, military service and other sources. Major BU ADRC research themes include studies on RHI from contact sports and military service and risk for AD/ADRD, including chronic traumatic encephalopathy (CTE) and deep phenotyping AD/ADRD heterogeneity with a range of complementary innovative approaches including digital and EEG phenotyping; neuropathology; genetics; biostatistical modelling; biomarker discovery; and molecular profiling. The BU ADRC will build on this strong record of accomplishment to support new research and educate the next generation of AD/ADRD scientists. The BU ADRC will also support high risk high gain innovative developmental projects focused on NAPA and NIA strategic goals and utilize our collective expertise and experience to facilitate career development of investigators with diverse backgrounds. The BU ADRC will develop new partnerships and enhance current partnerships with other ADRCs and national research programs, foundations, advocacy groups and private organizations in our quest to prevent and treat AD/ADRD. Exposure to RHI is associated with CTE and a wide range of other AD/ADRD pathologies. As recognized leaders in this space, we are uniquely positioned to support research on genetic and other risks factors and study how RHI affects the clinical course, biomarker profile, and clinical-pathological features of AD/ADRD including CTE.

波士顿大学阿尔茨海默病研究中心 (BU ADRC) 致力于实现以下目标： NAPA 的战略包括：到 2025 年预防和有效治疗 AD 和 AD 相关痴呆症 (ADRD) 扩大 AD/ADRD 研究；加快努力查明 AD/ADRD 的早期和症状前阶段；并教育公众有关 AD/ADRD 的知识。 BU ADRC 研究主题与 NIH AD/ADRD 一致研究峰会的建议包括：1）异质性和多因素性质的研究 AD/ADRD； 2) 现有和新队列的分子谱分析； 3）发展新的公私合作伙伴关系。我们通过 7 个紧密集成的核心来履行我们的使命：管理、临床 (CC)、数据管理和统计 (DMS)、生物标志物、神经病理学 (NPC)、外展/招募、参与 (ORE)、遗传学和分子分析 (GMP) 以及研究教育部分 (REC)。核心专注于前沿研究、积极的社区参与、培训下一代 AD/ADRD 临床医生和研究人员的产生，并在两者之间共享关键材料、数据和专业知识主要合作伙伴以及整个社区。 BU ADRC为该项目做出了重大贡献 AD/ADRD 研究在全国范围内取得显着增长，并积极贡献了参与者、生物所有主要国家 AD/ADRD 研究计划的样本、临床数据和科学专业知识。事业部 ADRC 一直是令人兴奋的关于遗传和生命周期环境风险因素的新研究的催化剂， AD/ADRD，特别是血管风险和接触性运动、军事造成的重复性头部撞击 (RHI) 服务和其他来源。 BU ADRC 的主要研究主题包括接触运动和 RHI 的研究服兵役和 AD/ADRD 风险，包括慢性创伤性脑病 (CTE) 和深部通过一系列互补的创新方法（包括数字化方法）对 AD/ADRD 异质性进行表型分型和脑电图表型分析；神经病理学；遗传学；生物统计模型；生物标志物发现；和分子分析。 BU ADRC 将以此为基础，支持新的研究和教育下一代 AD/ADRD 科学家。 BU ADRC 还将支持高风险高收益专注于 NAPA 和 NIA 战略目标并利用我们集体专业知识的创新发展项目和经验，以促进具有不同背景的研究者的职业发展。 BU ADRC 将发展新的伙伴关系并加强与其他 ADRC 和国家研究机构的现有伙伴关系项目、基金会、倡导团体和私人组织致力于预防和治疗 AD/ADRD。暴露于 RHI 与 CTE 和多种其他 AD/ADRD 病理相关。经认可作为该领域的领导者，我们具有独特的优势来支持遗传和其他风险因素的研究，研究 RHI 如何影响 AD/ADRD 的临床病程、生物标志物特征和临床病理特征包括 CTE。